

**24-hour\*  
ACE inhibition**

**ONCE-DAILY**  
**ZESTRIL!**  
LISINOPRIL-STUART

***BP control  
without compromise***

**Does not compromise  
metabolic abnormalities**

- glucose intolerance<sup>1,2</sup>
- insulin resistance<sup>2,3</sup>
- dyslipidemia<sup>1,2</sup>

**PREGNANCY WARNING: ACE inhibitors should be discontinued as soon as pregnancy is detected (see WARNINGS).**

Evaluation of the hypertensive patient should always include assessment of renal function (see DOSAGE AND ADMINISTRATION). Angioedema has been reported with ACE inhibitors, including ZESTRIL (see WARNINGS and CONTRAINDICATIONS).

\*The antihypertensive effect may diminish at the end of the dosing interval.

Please see adjacent page for brief summary of prescribing information.

**BRIEF SUMMARY FOR FULL PRESCRIBING INFORMATION, SEE PACKAGE INSERT**

**USE IN PREGNANCY**

When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, ZESTRIL should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

**INDICATIONS AND USAGE:** Hypertension: ZESTRIL is indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents.

**Heart Failure:** ZESTRIL is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. In using ZESTRIL, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that ZESTRIL does not have a similar risk. (See WARNINGS.)

**CONTRAINDICATIONS:** ZESTRIL is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor.

**WARNINGS: Angioedema:** Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors, including ZESTRIL. In such cases, ZESTRIL should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, eg, subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway should be promptly provided. (See ADVERSE REACTIONS.)

**Hypotension:** Excessive hypotension is rare in patients with uncomplicated hypertension treated with ZESTRIL alone. Patients with heart failure given ZESTRIL commonly have some reduction in blood pressure, with peak blood pressure reduction occurring 6 to 8 hours postdose, but discontinuation of therapy because of continuing symptomatic hypotension usually is not necessary when dosing instructions are followed; caution should be observed when initiating therapy. (See DOSAGE AND ADMINISTRATION.)

**Patients at risk of excessive hypotension:** sometimes associated with orthopnea and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure with systolic blood pressure below 100 mm Hg, hypotension, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. It may be advisable to eliminate the diuretic (except in patients with heart failure), reduce the diuretic dose or increase salt intake cautiously before initiating therapy with ZESTRIL in patients at risk for excessive hypotension who are able to tolerate such adjustments. (See PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS.)

**In patients at risk of excessive hypotension:** therapy should be started under very close medical supervision and such patients should be followed closely for the first two weeks of treatment and whenever the dose of ZESTRIL and/or diuretic is increased. Similar considerations may apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.

If excessive hypotension occurs, the patients should be placed in the supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses of ZESTRIL which usually can be given without difficulty once the blood pressure has stabilized. If symptomatic hypotension develops, a dose reduction or discontinuation of ZESTRIL or concomitant diuretic may be necessary.

**Neutropenia/Agranulocytosis:** Another angiotensin converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment especially if they also have a collagen vascular disease. Available data from clinical trials of ZESTRIL are insufficient to show that ZESTRIL does not cause agranulocytosis at similar rates. Marketing experience has revealed rare cases of neutropenia and bone marrow depression in which a causal relationship to lisinopril cannot be excluded. Periodic monitoring of white blood cell counts in patients with collagen vascular disease and renal disease should be considered.

**Fetal/Neonatal Morbidity and Mortality:** ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the world literature. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible. The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Aortic stenosis has also been reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to the ACE-inhibitor exposure.

These adverse effects do not appear to have resulted from intruterine ACE-inhibitor exposure that has been limited to the first trimester. Mothers whose embryos and fetuses are exposed to ACE inhibitors only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should make every effort to discontinue the use of ZESTRIL as soon as possible.

Rarely (probably less often than once in every thousand pregnancies), no alternative to ACE inhibitors will be found. In these rare cases, the mothers should be apprised of the potential hazards to their fetuses, and serial ultrasound examinations should be performed to assess the intra-amniotic environment. If oligohydramnios is observed, ZESTRIL should be discontinued. If amniotic fluid volume returns to normal, contraction stress testing (CST), a nonstress test (NST), or biophysical profilogram (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.

Infants with histories of in utero exposure to ACE inhibitors should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function. Lisinopril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion, although there is no experience with the latter procedure.

No teratogenic effects of lisinopril were seen in studies of pregnant rats, mice, and rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in rats), and 0.8 times (in rabbits) the maximum recommended human dose.

**PRECAUTIONS: General:** As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe congestive heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin converting enzyme inhibitors, including ZESTRIL, may be associated with orthopnea and/or progressive azotemia and rarely with acute renal failure and/or death.

In hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine may occur. Experience with another angiotensin converting enzyme inhibitor suggests that these increases are usually reversible upon discontinuation of ZESTRIL and/or diuretic therapy. In such patients, renal function should be monitored during the first few weeks of therapy.

Some patients with hypertension or heart failure with no apparent preexisting renal vascular disease have developed increases in blood urea nitrogen and serum creatinine, usually minor and transient, especially when ZESTRIL has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dose reduction and/or discontinuation of the diuretic and/or ZESTRIL may be required.

**Evaluation of patients with renal impairment or heart failure should include assessment of renal function. (See DOSAGE AND ADMINISTRATION.)**

**Hemodialysis Patients:** Sodium and potentially life-threatening anaphylactoid reactions have been reported in some patients dialyzed with high-flux membranes (eg, AN69) and treated concomitantly with an ACE inhibitor. In such patients, dialysis must be stopped immediately, and aggressive therapy for anaphylactoid reactions be initiated. Symptoms have not been relieved by antihistamines in these situations. In these patients, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.

**Hyperkalemia:** In clinical trials hyperkalemia (serum potassium greater than 5.7 mEq/L) occurred in approximately 2.2% of hypertensive patients and 4.8% of patients with heart failure. In most cases these were isolated values which resolved despite continued therapy. Hyperkalemia was a cause of discontinuation of therapy in approximately 0.1% of hypertensive patients and 0.6% of patients with heart failure. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with ZESTRIL. (See Drug Interactions.)

**Cough:** Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is nonproductive, persistent and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.

**Surgery/Anesthesia:** In patients undergoing major surgery or during anesthesia with agents that produce hypotension, ZESTRIL may block angiotensin II information secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.

**Information for Patients:** Angioedema: Angioedema, including laryngeal edema, may occur especially following the first dose of ZESTRIL. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.

**Symptomatic Hypotension:** Patients should be cautioned to report light-headedness especially during the first few days of therapy. If actual syncope occurs, the patient should be told to discontinue the drug until they have consulted with the prescribing physician.

All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with their physician.

**Hyperkalemia:** Patients should be told to not use salt substitutes containing potassium without consulting their physician.

**Neutropenia:** Patients should be told to report promptly any indication of infection (eg, sore throat, fever) which may be a sign of neutropenia.

**Pregnancy:** Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intruterine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

**NOTE:** As with many other drugs, certain advice to patients being treated with ZESTRIL is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

**Drug Interactions: Hypotension - Patients on Diuretic Therapy:** Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ZESTRIL. The possibility of hypotensive effects with ZESTRIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with ZESTRIL. If it is necessary to continue the diuretic, initiate therapy with ZESTRIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized. (See WARNINGS, and DOSAGE AND ADMINISTRATION.) When a diuretic is added to the therapy of a patient receiving ZESTRIL, an additional antihypertensive effect is usually observed. Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic. (See DOSAGE AND ADMINISTRATION.)

**Indomethacin:** In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of ZESTRIL alone were compared to ZESTRIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced effect, although the difference between the two regimens was not significant.

**Other Agents:** ZESTRIL has been used concomitantly with nitrate and/or digoxin without evidence of clinically significant adverse interactions. An clinically important pharmacokinetic interaction occurred when ZESTRIL was used concomitantly with propranolol or hydrochlorothiazide. The presence of food in the stomach does not alter the bioavailability of ZESTRIL.

**Agents Increasing Serum Potassium:** ZESTRIL attenuates potassium loss caused by thiazide-type diuretics. Use of ZESTRIL with potassium-sparing diuretics (eg, spironolactone, triamterene or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. Potassium-sparing agents should generally not be used in patients with heart failure who are receiving ZESTRIL.

**Lithium:** Lithium toxicity has been reported in patients receiving lithium with drugs which cause elimination of sodium, including ACE inhibitors. Lithium toxicity was usually reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if ZESTRIL is administered concomitantly with lithium.

**Carotidogram, Metagenesis, Impairment of Fertility:** There was no evidence of a teratogenic effect when lisinopril was administered for 106 weeks to male and female rats at doses up to 90 mg/kg/day (about 56 or 9 times the maximum recommended daily human dose, based on body weight and body surface area, respectively). There was no evidence of carcinogenicity when lisinopril was administered for 92 weeks to (male and female) mice at doses up to 135 mg/kg/day (about 84 times the maximum recommended daily human dose). This was 6.8 times the maximum human dose based on body surface area in mice.

**Calculations assume a human weight of 50 kg and human body surface area of 1.62 m<sup>2</sup>.**

Lisinopril was not mutagenic in the Ames microbial mutagen test with or without metabolic activation. It was also negative in a forward mutation assay using Chinese hamster lung cells. Lisinopril did not produce single strand DNA breaks in an *in vitro* alkaline elution test hepatocyte assay. In addition, lisinopril did not produce increases in chromosomal aberrations in an *in vitro* test in Chinese hamster ovary cells or in an *in vivo* study in mouse bone marrow.

There were no adverse effects on reproductive performance in male and female rats treated with up to 300 mg/kg/day of lisinopril. This dose is 188 times and 30 times the maximum human dose when based on mg/kg and mg/m<sup>2</sup>, respectively.

**Pregnancy: Pregnancy Categories C (first trimester) and D (second and third trimesters).** See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

**Nursing Mothers:** Milk of lactating rats contains radioactively following administration of <sup>14</sup>C lisinopril. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from ACE inhibitors, a decision should be made whether to discontinue nursing and/or discontinue ZESTRIL, taking into account the importance of the drug to the mother.

**Pediatric Use:** Safety and effectiveness in children have not been established.

**ADVERSE REACTIONS:** ZESTRIL has been found to be generally well tolerated in controlled clinical trials involving 1969 patients. For the most part, adverse experiences were mild and transient.

In clinical trials with hypertension treated with ZESTRIL, discontinuation of therapy due to clinical adverse experiences occurred in 5.7% of patients. The overall frequency of adverse experiences could not be related to total daily dosage within the recommended therapeutic dosage range.

In patients with heart failure treated with ZESTRIL for up to four years, discontinuation of therapy due to clinical adverse experiences occurred in 11.0% of

patients. In controlled studies in patients with heart failure, therapy was discontinued in 8.1% of patients treated with ZESTRIL for 12 weeks, compared to 7.7% of patients treated with placebo for 12 weeks.

**Hyperkalemia:** For adverse experiences occurring in greater than 1% of patients with hypertension treated with ZESTRIL, or ZESTRIL plus hydrochlorothiazide in controlled clinical trials, comparative incidence data are listed in the table below.

	PERCENT OF PATIENTS IN CONTROLLED STUDIES			Discontinued Therapy		AT Risk ZESTRIL (n=62)
	ZESTRIL (n=348)	ZESTRIL+Hydrochlorothiazide (n=207)	PLACEBO (n=207)	ZESTRIL (n=47)	Placebo (n=155)	
	(%)	(%)	(%)	(%)	(%)	(%)

Body as a Whole	ZESTRIL (n=348)	ZESTRIL+Hydrochlorothiazide (n=207)	PLACEBO (n=207)	ZESTRIL (n=47)	Placebo (n=155)	AT Risk ZESTRIL (n=62)
Fatigue	25 (0.9)	4.0 (0.5)	1.0 (0.0)			
Headache	13 (0.5)	2.1 (0.2)	1.0 (0.0)			
Chest Pain	12 (0.1)	1.3 (0.2)	1.4 (0.0)			
Orthostatic Effects	12 (0.0)	3.5 (0.2)	1.0 (0.0)			

Cardiovascular	ZESTRIL (n=348)	ZESTRIL+Hydrochlorothiazide (n=207)	PLACEBO (n=207)	ZESTRIL (n=47)	Placebo (n=155)	AT Risk ZESTRIL (n=62)
Hypotension	12 (0.5)	1.6 (0.5)	0.5 (0.5)			
Dizziness	27 (0.2)	2.7 (0.3)	2.4 (0.0)			
Nausea	20 (0.4)	2.5 (0.2)	2.4 (0.0)			
Vertigo	11 (0.2)	1.4 (0.1)	0.5 (0.0)			
Dyspnea	0.9 (0.0)	1.9 (0.0)	0.0 (0.0)			

Respiratory	ZESTRIL (n=348)	ZESTRIL+Hydrochlorothiazide (n=207)	PLACEBO (n=207)	ZESTRIL (n=47)	Placebo (n=155)	AT Risk ZESTRIL (n=62)
Cough	27 (0.2)	2.7 (0.3)	2.4 (0.0)			
Upper Respiratory Infection	21 (0.1)	2.7 (0.1)	0.0 (0.0)			
Common Cold	11 (0.1)	1.3 (0.1)	0.0 (0.0)			
Nasal Congestion	0.4 (0.1)	1.3 (0.1)	0.0 (0.0)			
Laryngitis	0.3 (0.1)	1.1 (0.1)	0.0 (0.0)			
Rash	1.3 (0.4)	1.6 (0.2)	0.5 (0.5)			
Urticaria						
Pruritus						

Other clinical adverse experiences occurring in 0.3% to 1.0% of patients with hypertension or heart failure treated with ZESTRIL in controlled clinical trials and rarer, possibly drug-related events reported in uncontrolled studies or marketing experience are listed below, and within each category are in order of decreasing severity.

**Body as a Whole:** Anaphylactoid reactions (see PRECAUTIONS, Hemodialysis patients), chest discomfort, pain, pelvic pain, flank pain, facial edema, peripheral edema, virus infection, chills.

**Cardiovascular:** Cardiac arrest, myocardial infarction or cerebrovascular accident possibly secondary to excessive hypotension in high risk patients (see WARNINGS, Hypotension); pulmonary embolism and infarction, arrhythmias (including ventricular tachycardia, atrial tachycardia, atrial fibrillation, bradycardia and premature ventricular contractions), transient ischemic attacks, paroxysmal nocturnal dyspnea, decreased blood pressure, peripheral edema, vasculitis.

**Digestive:** Pancreatitis, hepatitis (hepatocellular or cholestatic jaundice), gastritis, heartburn, gastrointestinal cramps, constipation, flatulence, dry mouth.

**Psychiatric:** Rare cases of bone marrow depression, neutropenia and thrombocytopenia.

**Endocrine:** Diabetes mellitus.

**Metabolic:** Weight loss, dehydration, fluid overload, weight gain.

**Musculoskeletal:** Arthritis, arthralgia, neck pain, hip pain, low back pain, joint pain, knee pain, shoulder pain, arm pain, lump/bump.

**Nervous System/Psychiatric:** Stroke, ataxia, memory impairment, tremor, spasm, confusion, somnolence, hypersomnia, irritability and nervousness.

**Respiratory System:** Malignant lung neoplasms, hemoptysis, asthma, pleural effusion, pneumonia, wheezing, orthopnea, painful respiration, epistaxis, laryngitis, sinusitis, pharyngitis, pharyngitis, rhinitis, rhinorrhea.

**Skin:** Urticaria, alopecia, herpes zoster, photosensitivity, skin lesion, skin infections, erythema, flushing, diaphoresis.

**Special Senses:** Visual loss, diplopia, blurred vision, tinnitus, photophobia.

**Urogenital System:** Acute renal failure, oliguria, anuria, uremia, progressive azotemia, renal dysfunction (see PRECAUTIONS and DOSAGE AND ADMINISTRATION), polydipsia, dysuria, breast pain.

**Miscellaneous:** A symptom complex has been reported which may include a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia, fever, vasculitis, eosinophilia and leukocytosis. Rash, photosensitivity or other dermatological manifestations may occur alone or in combination with these symptoms.

**ANGIOEDEMA:** Angioedema has been reported in patients receiving ZESTRIL (0.1%). Angioedema associated with laryngeal edema may be fatal. The angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with ZESTRIL should be discontinued and appropriate therapy instituted immediately. (See WARNINGS.)

**HYPOTENSION:** In hypertensive patients, hypotension occurred in 1.2% and syncope occurred in 0.1% of patients. Hypotension or syncope was a cause of discontinuation of therapy in 0.5% of hypertensive patients. In patients with heart failure, hypotension occurred in 5.3% and syncope occurred in 1.8% of patients. These adverse experiences were causes for discontinuation of therapy in 1.8% of these patients. (See WARNINGS.)

**Fetal/Neonatal Morbidity and Mortality:** See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

**Cough:** See PRECAUTIONS - Cough.

**Clinical Laboratory Test Findings**

**Serum Electrolytes:** Hyperkalemia: (See PRECAUTIONS.)

**Creatinine, Blood Urea Nitrogen:** Minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 2.0% of patients with essential hypertension treated with ZESTRIL alone. Increases were more common in patients receiving concomitant diuretics and in patients with renal artery stenosis. (See PRECAUTIONS.) Reversible minor increases in blood urea nitrogen and serum creatinine were observed in approximately 11.8% of patients with congestive heart failure on concomitant diuretic therapy. Frequently, these abnormalities resolved when the dosage of the diuretic was decreased.

**Hemoglobin and Hematocrit:** Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.4 g/dL and 1.3 vol%, respectively) occurred frequently in patients treated with ZESTRIL but were rarely of clinical importance in patients without other causes of anemia. Clinical trials, less than 0.1% of patients discontinued therapy due to anemia.

**Liver Function Tests:** Rarely, elevations of liver enzymes and/or serum bilirubin have occurred.

In hypertensive patients, 2.0% discontinued therapy due to laboratory adverse experiences, principally elevations in blood urea nitrogen (0.6%), serum creatinine (0.3%) and serum potassium (0.4%).

In the heart failure trials, 3.4% of patients discontinued therapy due to laboratory adverse experiences: 1.8% due to elevations in blood urea nitrogen and/or creatinine (0.8% due to elevations in serum potassium).

**OVERDOSAGE:** Following a single oral dose of 20 mg no lethality occurred in rats and death occurred in one of 20 mice receiving the same dose. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution.

Lisinopril can be removed by hemodialysis.

**DOSAGE AND ADMINISTRATION: Hypertension:** Initial Therapy. In patients with uncomplicated essential hypertension not on diuretic therapy, the recommended initial dose is 10 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dose range is 20-40 mg per day, administered in a single daily dose. If blood pressure is not controlled with ZESTRIL alone, a low dose of a diuretic may be added. Hydrochlorothiazide, 12.5 mg, has been shown to provide an additive effect. After the addition of a diuretic, it may be possible to reduce the dose of ZESTRIL.

**Diuretic Treated Patients:** In hypertensive patients who are currently being treated with a diuretic, symptomatic hypotension may occur occasionally following the initial dose of ZESTRIL. The diuretic should be discontinued, if possible, for two to three days before beginning therapy with ZESTRIL to reduce the likelihood of hypotension (see WARNINGS).

If the diuretic cannot be discontinued, an initial dose of 5 mg should be used under medical supervision for at least 2 hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and PRECAUTIONS, Drug Interactions.)

Concomitant administration of ZESTRIL with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics may lead to increases of serum potassium (see PRECAUTIONS).

**Dosage Adjustment in Renal Impairment:** The usual dose of ZESTRIL (10 mg) is recommended for patients with creatinine clearance > 30 mL/min (serum creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance ≥ 10 mL/min < 30 mL/min (serum creatinine ≥ 3 mg/dL), the first dose is 5 mg once daily. For patients with creatinine clearance < 10 mL/min (usually on hemodialysis) the recommended initial dose is 2.5 mg. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily.

**Heart Failure:** ZESTRIL is indicated as adjunctive therapy with diuretics and digitalis. The recommended starting dose is 5 mg once a day. When initiating therapy with lisinopril in patients with heart failure the initial dose should be administered under medical observation, especially in those patients with low blood pressure (systolic blood pressure below 100 mm Hg). The mean peak blood pressure lowering occurs six to eight hours after dosing. Observation should continue until blood pressure is stable. The concomitant diuretic dose should be reduced, if possible, to help minimize hypovolemia which may contribute to hypotension. (See WARNINGS and PRECAUTIONS, Drug Interactions.) The appearance of hypotension after the initial dose of ZESTRIL does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension.

If the usual effective dosage range is 5 to 20 mg per day administered as a single daily dose.

**Dosage Adjustment in Patients with Heart Failure and Renal Impairment or Hypotension:** In patients with heart failure who have hypotension (serum sodium < 130 mEq/L) or moderate to severe renal impairment (creatinine clearance ≤ 30 mL/min or serum creatinine > 3 mg/dL), therapy with ZESTRIL should be initiated at a dose of 2.5 mg once a day under close medical supervision. (See WARNINGS and PRECAUTIONS, Drug Interactions.)

**Use in Elderly:** In general, blood pressure response and adverse experiences were similar in younger and older patients given similar doses of ZESTRIL. Pharmacokinetic studies, however, indicate that maximum blood levels and area under the plasma concentration time curve (AUC) are doubled in older patients, so that dosage adjustments should be made with particular caution.

**HOW SUPPLIED**

5 mg Tablets (NDC 0038-0130) pink, capsule-shaped, biconvex, bisected, uncoated tablets, identified "ZESTRIL" on one side and "130" on the other side, are supplied in bottles of 100 tablets and 1000 tablets and unit dose packages of 100 tablets.

10 mg Tablets (NDC 0038-0131) pink, round, biconvex, uncoated tablets, identified "ZESTRIL 10" debossed on one side and "131" debossed on the other side, are supplied in bottles of 100 tablets and 1000 tablets and unit dose packages of 100 tablets.

20 mg Tablets (NDC 0038-0132) red, round, biconvex, uncoated tablets, identified "ZESTRIL 20" debossed on one side and "132" debossed on the other side, are supplied in bottles of 100 tablets and 1000 tablets and unit dose packages of 100 tablets.

40 mg Tablets (NDC 0038-0134) yellow, round, biconvex, uncoated tablets, identified "ZESTRIL 40" debossed on one side and "134" debossed on the other side, are supplied in bottles of 100 tablets and 1000 tablets and unit dose packages of 100 tablets.

Store at controlled room temperature, 15°C to 30°C (59°F to 86°F). Protect from moisture, freezing and excessive heat. Dispense in a tight container.

Registered trademark of Hospal Ltd.

STUART PHARMACEUTICALS A business unit of ZENECA Inc. Wilmington, DE 19897 USA

# Two Reasons to Join ADA Today:

- 1** You Choose the Journals You Want to Receive!
- 2** Join Now and You Save on Scientific Sessions Registration

Fax your credit card order to  
(703) 549-6995

## Introducing ADA's Cafeteria-Style Membership

The American Diabetes Association now offers two low-priced Professional Section membership options that let you receive the publications *you want*—at a price that fits your budget.

**Category I**—Entitles you to choose between *Diabetes* or *Diabetes Care*, plus the opportunity to subscribe to additional ADA journals at reduced member prices. Please note, physicians must join this category.

**Category II**—Entitles you to *Diabetes Spectrum*, plus the opportunity to subscribe to additional ADA journals at reduced member prices.

Both membership categories offer a wide range of benefits, including discounts on ADA's Scientific Sessions, Postgraduate

Course, and other educational programs; the Professional Section *Membership Directory*; eligibility for ADA research grants and awards; one free Professional Section Council membership; local ADA affiliate membership; the *Professional Section News*; and *Clinical Practice Recommendations* and a discount to *BRS Colleague*.

### In-Training Membership Rates

You are eligible to become a Member-In-Training if you have received your first professional degree within the last five years. This qualifies you for dues at half-price. Also, you will be eligible to subscribe to additional ADA journals at the same reduced rates as other members.

## Exclusive Member Benefits

### Your Choice of Publications

***Diabetes***—the world's most-cited journal of basic diabetes research brings you the latest findings from the world's top scientists.

***Diabetes Care***—the premier journal of clinical diabetes research and treatment. *Diabetes Care* keeps you current with original research reports, commentaries, and reviews.

***Diabetes Review Issues***—the comprehensive but concise review articles in ADA's newest journal are a convenient way for the busy clinician to keep up-to-date on what's truly new in research.

***Diabetes Spectrum***—translates research into practice for nurses, dietitians, and other health-care professionals involved in patient education and counseling.

***Clinical Diabetes***—For the primary-care physician as well as other health-care professionals, this newsletter offers articles and abstracts highlighting recent advances in diabetes treatment.

***Diabetes Forecast***—ADA's magazine for patients and their families features advice on diet, exercise, and other lifestyle changes, plus the latest developments in new technology and research. It is a valuable tool for patient education.

***1994 Scientific Sessions Abstract Book***—given out at the door to all Scientific Sessions attendees, the *Abstract Book* is available through the mail, for a small fee, if you want to receive an advance copy or are unable to attend the meeting.

### Professional Section News

This quarterly newsletter highlights Professional Section events and other ADA news.

### FREE Council Membership

Professional Section Councils give you an opportunity to network

with members from different specialties who share your interest in a specific area of diabetes research or care. One free Council membership is included with your membership. Additional Council memberships are available for \$25 each.

### Membership Directory Listing

Your link to a valuable network of more than ten thousand diabetes experts. Locate your colleagues by specialty, location, and Professional Section Council membership.

### Eligibility for ADA Research Grants and Awards

An exclusive benefit. Only members of the Professional Section are eligible to receive ADA grants that support diabetes research. In addition, annual awards are presented to physicians, diabetes educators, and researchers to honor outstanding performance.

### Discounts on ADA Scientific and Medical Programs

Save on registration for ADA's Scientific Sessions, Postgraduate Course, and ADA-sponsored symposia. ADA meetings are accredited for CME credits.

### Local Affiliate Membership

Your Professional Section membership also entitles you to membership in your local ADA affiliate where you can participate in patient and professional education programs, network with other professionals, and actively participate in shaping the future of ADA.

### Clinical Practice Recommendations

This extensive guide details the current ADA standards of clinical care. The position statements and technical reviews in *Clinical Practice Recommendations* are convenient and important resources for all health-care professionals who care for people with diabetes.



# Introducing Diabetes Reviews

**Imagine going to a seminar with the world's leading diabetes investigators ... without leaving your office**

If you're like the average clinician treating diabetes, you probably have a tough time keeping up with all of the latest basic and clinical diabetes research. *Diabetes Reviews*, the new quarterly review journal from the American Diabetes Association, can help. In its pages, top investigators discuss their latest findings, explain how they relate to previous data, and point out the clinical significance of the work. Each issue is like completing a postgraduate course in diabetes.

Contributors are chosen to offer the broadest possible perspective on a given subject. *Diabetes Reviews* will cover the topics that clinicians face most often, including:

- complications of IDDM and NIDDM
- methods of achieving and effects of good glycemic control
- drug treatment, including mechanism of action
- exercise therapy
- management of lipid disorders
- epidemiology of diabetes and its complications  
and much more

Edited by noted diabetes investigator Ralph DeFronzo of the University of Texas, *Diabetes Reviews* will bring you to the frontiers of diabetes research. It is a must read for any clinician who wants to keep up-to-date on the most quickly advancing areas of clinical and basic research.

✂.....

Please begin my charter subscription to *Diabetes Reviews*.<sup>\*</sup> My payment of \$30 is enclosed (outside the US, Canada, & Mexico please enclose \$41).

Name/Degree: \_\_\_\_\_

Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

J39DRCR1

Return this form with payment to: American Diabetes Association  
Professional Journal Subscriptions  
1660 Duke Street  
Alexandria, VA 22314

Method of payment:

Check or money order  VISA  MasterCard  American Express

Card #: \_\_\_\_\_

Exp Date: \_\_\_\_\_

Signature: \_\_\_\_\_

<sup>\*</sup> *Diabetes Reviews* begins quarterly publication with the March 1993 issue. All orders must be paid in US funds, drawn on a US bank. Canadians add 7% GST tax.

# Diabetic Medicine

Journal of the British Diabetic Association

## EDITORIAL

- Footwear and Orthoses for Diabetic Patients** A. B. Ward ..... 497

## REVIEWS

- Complications of Diabetes in Childhood** J. P. H. Shield, J. D. Baum ..... 499
- Recurrent Severe Hypoglycaemia and Cognitive Function in Type 1 Diabetes** A. E. Gold, I. J. Deary, B. M. Frier ..... 503

## ORIGINAL ARTICLES

- Diet Treatment of Newly Presenting Type 2 Diabetes Improves Insulin Secretory Capacity, but Has No Effect on Insulin Sensitivity** J. P. Hosker, S. Kumar, C. Gordon, D. Bhatnagar, M. France, A. J. M. Boulton ..... 509
- The Degree of Day-to-day Variation in Food Intake in Diabetic Patients** E. J. Close, P. G. Wiles, J. A. Lockton, D. Walmsley, J. Oldham, J. K. Wales ..... 514
- No Increased Prevalence of Type 1 Diabetes Mellitus at Follow-up of Swedish Infants Congenitally Infected with Cytomegalovirus** S.-A. Ivarsson, B. Lindberg, K. O. Nilsson, K. Ahlors, L. Svanberg ..... 521
- Glucose Profiles in Children Two Years After the Onset of Type 1 Diabetes** T. Simell, O. Simell, E. Lammi, E. A. Kaprio, A. Hakulinen, J. Hakalax, J. Mäenpää ..... 524
- Psychological Factors and Their Relationship to Diabetes Control** D. Gordon, S. G. Fisher, M. Wilson, E. Fergus, K. R. Paterson, C. G. Semple ..... 530
- Action Profile of the Rapid Acting Insulin Analogue: Human Insulin B28Asp** L. Heinemann, T. Heise, L. N. Jorgensen, A. A. R. Starke ..... 535
- Pregnancy is Not a Risk Factor for a Deterioration of Autonomic Nervous Function in Diabetic Women** K. E. J. Airaksinen, P. I. Salmela ..... 540
- A Prospective Study of Clinical and Metabolic Associates of Proteinuria in Patients with Type 2 Diabetes Mellitus** L. Niskanen, R. Voutilainen, M. Teräsvirta, J. Lehtinen, A.-M. Teppo, L. Groop, M. Uusitupa ..... 543

## CLINICAL PRACTICE

- Bacteriuria, Bacterial Virulence and Host Factors in Diabetic Patients** A. Brauner, U. Flodin, B. Hylander, C.-G. Östenson ..... 550
- The Five-year Incidence of Blindness after Introducing a Screening Programme for Early Detection of Treatable Diabetic Retinopathy** E. Agardh, C.-D. Agardh, C. Hansson-Lundblad ..... 555
- Accurate and Precise Blood Glucose Measurement in the Hypoglycaemic Range** K. L. Tieszen, A. W. Patrick, E. Smith, G. Williams, T. L. Dornan ..... 560
- Glycated Haemoglobin Centiles: A Basis for Audit in Children's Clinics?** J. K. H. Wales, A. R. W. Forrest ..... 564
- An Approach to the Use of the DO IT Study Group Guidelines for Supporting the Optimal Implementation of Information Systems in Diabetes Care** J. R. Flack, P. D. Home ..... 568

## CASE REPORT

- Emphysematous Pyelonephritis: a Case Report and Review of the Literature** S. Pappas, Th. A. Peppas, A. Sotiropoulos, D. Katsadoros ..... 574

## MEETING REPORT

- Awareness of Hypoglycaemia—Problems and Perspectives, London, December 1992** S. Pinn, E. A. M. Gale ..... 577

## LETTERS

- Severe Lipoatrophy with Human Insulin: Successfully Treated by CSII** E. Chantelau, M. Reuter, S. Schotes, A. A. R. Starke ..... 580
- Editorial Guidelines for the Methods Section of Dietary Investigations** M. Nelson, B. M. Margetts, A. E. Black ..... 581

Forthcoming Papers, 493 • DM Diary, 495 • 'Diabetes Care' Contents Page, 583



0742-3071(199307)10:6;1-N




WILEY

A WILEY MEDICAL PUBLICATION

DIMEEV 10(6) 489-584 (1993)

ISSN 0742-3071

# About Your Diabetes is now within your reach.



Under  
**\$3000\***  
including  
hardware  
and  
software.

Visit USP at Booth 430-432 at the American Diabetes Association's  
53rd Annual Meeting June 12-15

## Affordable interactive training for diabetes patients.

Experience shows that interactive training is one of the fastest, most productive ways to instruct your diabetes patients about managing their health. Now, with the development of the next generation of *USP DI Visualized - About Your Diabetes™*, USP has taken interactive training to an even higher level of efficiency — at a remarkably low price.

**An exciting way to learn:** Colorful graphics, high quality audio, and real life scenarios actively involve your patients with a complete database of diabetes management information.

**Customized content:** Learning is enjoyable, self-paced and completely personalized to each patient's unique condition.

**Vital diet and nutrition exercises:** Enhanced meal plan information and exercises included.

**Easy to use:** The single unit Compact Disc Interactive (CD-I) player is lightweight, portable, and plugs into any TV monitor for instant operation.

**Simple data analysis and storage:** Create on-screen reports to assess patient comprehension. Save patient record information on floppy disk.

Compare the advantages of *About Your Diabetes* to any other diabetes patient education system. You'll see that it's a value you can't afford to pass up.



**For more information call USP's Marketing Department at 1-800-227-8772, or use the following coupon.**

\*Hardware prices may vary with market and your choice of peripherals.

**Yes**, I'm interested in *About Your Diabetes*. Send me more information.

Name \_\_\_\_\_ Title \_\_\_\_\_

Organization \_\_\_\_\_

Address \_\_\_\_\_




City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Phone (\_\_\_\_) \_\_\_\_\_

Send to: **The U.S. Pharmacopeial Convention, Inc.**  
12601 Twinbrook Parkway Rockville, MD 20852

**USP. Information is your most valuable tool.**

L I F E S C A N S <sup>SM</sup> B Y • L I F E S C A N



ONE TOUCH<sup>®</sup> simplicity. At a price that's a light touch.

## Put more value in your patients' lives.

Managing diabetes takes accurate and timely information. That means blood glucose measurements not just in your office or lab, but in your patients' lives. And that means a meter that fits their lives—and their budgets. Which describes the ONE TOUCH<sup>®</sup> BASIC<sup>™</sup> Blood Glucose Meter. It's the only low-price meter to incorporate proven, accurate ONE TOUCH<sup>®</sup> technology—the no-wipe technology that's recommended by more physicians, diabetes educators and pharmacists.\* In fact, it's so easy to use it encourages compliance. Available in drugstores and home healthcare centers, the ONE TOUCH<sup>®</sup> BASIC<sup>™</sup> Meter comes with a 30-day, money-back guarantee from LifeScan, a Johnson & Johnson company. Not to mention a 24-hour customer services line for your patients and a separate Healthcare Professional Hotline for *your* patience. To find out more, call 1 800 524-7226. LifeScan, for diabetes and life.



**ONE TOUCH<sup>®</sup>**  
**BASIC<sup>™</sup>**

BLOOD GLUCOSE MONITORING SYSTEM

\*Data on file

\*\*\$25 cash back rebate and/or \$25 meter trade-in for a limited time only